ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts [Seeking Alpha]
ArriVent BioPharma (NASDAQ:AVBP) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer [Yahoo! Finance]
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B